These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1561919)

  • 21. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in monitoring of adverse drug reactions in Poland.
    Czarnecki A; Maciejczyk A
    Acta Pol Pharm; 1998; 55(4):319-21. PubMed ID: 9821398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the Netherlands.
    Becker ML; Caspers PW; Kallewaard M; Bruinink RJ; Kylstra NB; Heisterkamp S; de Valk V; van der Veen AA; Stricker BH
    Pharm World Sci; 2007 Apr; 29(2):51-7. PubMed ID: 17187223
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of a database computer program to identify trends in reporting of adverse drug reactions.
    Johnston PE; Morrow JD; Branch RA
    Am J Hosp Pharm; 1990 Jun; 47(6):1321-7. PubMed ID: 2368725
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symmetry analysis for monitoring safety of newly marketed drugs.
    Kubota K
    Pharmacoepidemiol Drug Saf; 2016 Mar; 25(3):349-51. PubMed ID: 26440748
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postmarketing surveillance.
    Oleen MA
    Can J Hosp Pharm; 1987 Oct; 40(5):171-2, 179-80. PubMed ID: 10284449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early detection of adverse drug events within population-based health networks: application of sequential testing methods.
    Brown JS; Kulldorff M; Chan KA; Davis RL; Graham D; Pettus PT; Andrade SE; Raebel MA; Herrinton L; Roblin D; Boudreau D; Smith D; Gurwitz JH; Gunter MJ; Platt R
    Pharmacoepidemiol Drug Saf; 2007 Dec; 16(12):1275-84. PubMed ID: 17955500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved reporting of adverse drug reactions.
    Kimelblatt BJ; Young SH; Heywood PM; Mandala AR; Gendelman S; Mehl B
    Am J Hosp Pharm; 1988 May; 45(5):1086-9. PubMed ID: 3400650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a videotape on adverse drug reactions.
    Morgan SA; Frank JT
    Am J Hosp Pharm; 1990 Jun; 47(6):1340-2. PubMed ID: 1695062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Drug safety: from development to clinical use].
    Ovchinnikova EA; Gerasimov VB
    Antibiot Khimioter; 2006; 51(6):15-22. PubMed ID: 17523417
    [No Abstract]   [Full Text] [Related]  

  • 32. Evaluating the completeness and accuracy of MedWatch data.
    Getz KA; Stergiopoulos S; Kaitin KI
    Am J Ther; 2014; 21(6):442-6. PubMed ID: 23011177
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reporting of fatal adverse drug reactions.
    Liu BA; Knowles SR; Mittmann N; Einarson T; Shear NH
    Can J Clin Pharmacol; 2001; 8(2):84-8. PubMed ID: 11493936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The state of adverse event reporting and signal generation of dietary supplements in Korea.
    Park KS; Kwon O
    Regul Toxicol Pharmacol; 2010 Jun; 57(1):74-7. PubMed ID: 20074608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety profile of oxcarbazepine: results from a prescription-event monitoring study.
    Buggy Y; Layton D; Fogg C; Shakir SA
    Epilepsia; 2010 May; 51(5):818-29. PubMed ID: 20132298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient reporting of adverse drug reactions: useful information for pain management?
    Jarernsiripornkul N; Krska J; Richards RM; Capps PA
    Eur J Pain; 2003; 7(3):219-24. PubMed ID: 12725844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel algorithm for detection of adverse drug reaction signals using a hospital electronic medical record database.
    Park MY; Yoon D; Lee K; Kang SY; Park I; Lee SH; Kim W; Kam HJ; Lee YH; Kim JH; Park RW
    Pharmacoepidemiol Drug Saf; 2011 Jun; 20(6):598-607. PubMed ID: 21472818
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse drug reactions and reporting.
    Witte R
    Clin J Oncol Nurs; 2000; 4(4):181, 184. PubMed ID: 11261100
    [No Abstract]   [Full Text] [Related]  

  • 39. Strategies to increase the sensitivity of pharmacovigilance in Portugal.
    Ribeiro-Vaz I; Herdeiro MT; Polónia J; Figueiras A
    Rev Saude Publica; 2011 Feb; 45(1):129-35. PubMed ID: 21085884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how?
    Trifirò G; Coloma PM; Rijnbeek PR; Romio S; Mosseveld B; Weibel D; Bonhoeffer J; Schuemie M; van der Lei J; Sturkenboom M
    J Intern Med; 2014 Jun; 275(6):551-61. PubMed ID: 24635221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.